Vietnam · Delayed Price · Currency is VND Imexpharm Statistics
Total Valuation
Imexpharm has a market cap or net worth of VND 8.32 trillion. The enterprise value is 8.13 trillion.
| Market Cap | 8.32T |
| Enterprise Value | 8.13T |
Important Dates
The last earnings date was Friday, January 16, 2026.
| Earnings Date | Jan 16, 2026 |
| Ex-Dividend Date | Jun 9, 2025 |
Share Statistics
Imexpharm has 154.01 million shares outstanding.
| Current Share Class | 154.01M |
| Shares Outstanding | 154.01M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -4.35% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.68% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 27.32 and the forward PE ratio is 22.65.
| PE Ratio | 27.32 |
| Forward PE | 22.65 |
| PS Ratio | 3.41 |
| PB Ratio | 3.61 |
| P/TBV Ratio | 3.72 |
| P/FCF Ratio | 304.72 |
| P/OCF Ratio | 153.52 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.38, with an EV/FCF ratio of 297.81.
| EV / Earnings | 26.70 |
| EV / Sales | 3.33 |
| EV / EBITDA | 14.38 |
| EV / EBIT | 17.58 |
| EV / FCF | 297.81 |
Financial Position
The company has a current ratio of 4.05, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.05 |
| Quick Ratio | 2.05 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.38 |
| Debt / FCF | 7.80 |
| Interest Coverage | 28.02 |
Financial Efficiency
Return on equity (ROE) is 15.55% and return on invested capital (ROIC) is 16.85%.
| Return on Equity (ROE) | 15.55% |
| Return on Assets (ROA) | 10.93% |
| Return on Invested Capital (ROIC) | 16.85% |
| Return on Capital Employed (ROCE) | 19.19% |
| Weighted Average Cost of Capital (WACC) | 8.15% |
| Revenue Per Employee | 1.68B |
| Profits Per Employee | 209.06M |
| Employee Count | 1,456 |
| Asset Turnover | 0.92 |
| Inventory Turnover | 1.85 |
Taxes
In the past 12 months, Imexpharm has paid 97.11 billion in taxes.
| Income Tax | 97.11B |
| Effective Tax Rate | 21.76% |
Stock Price Statistics
The stock price has increased by +22.62% in the last 52 weeks. The beta is 0.72, so Imexpharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | +22.62% |
| 50-Day Moving Average | 51,021.00 |
| 200-Day Moving Average | 50,982.75 |
| Relative Strength Index (RSI) | 65.69 |
| Average Volume (20 Days) | 51,093 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imexpharm had revenue of VND 2.44 trillion and earned 304.39 billion in profits. Earnings per share was 1,976.44.
| Revenue | 2.44T |
| Gross Profit | 1.16T |
| Operating Income | 462.44B |
| Pretax Income | 446.25B |
| Net Income | 304.39B |
| EBITDA | 565.41B |
| EBIT | 462.44B |
| Earnings Per Share (EPS) | 1,976.44 |
Balance Sheet
The company has 401.30 billion in cash and 212.78 billion in debt, with a net cash position of 188.52 billion or 1,224.06 per share.
| Cash & Cash Equivalents | 401.30B |
| Total Debt | 212.78B |
| Net Cash | 188.52B |
| Net Cash Per Share | 1,224.06 |
| Equity (Book Value) | 2.31T |
| Book Value Per Share | 14,976.55 |
| Working Capital | 1.13T |
Cash Flow
In the last 12 months, operating cash flow was 54.17 billion and capital expenditures -26.88 billion, giving a free cash flow of 27.29 billion.
| Operating Cash Flow | 54.17B |
| Capital Expenditures | -26.88B |
| Free Cash Flow | 27.29B |
| FCF Per Share | 177.21 |
Margins
Gross margin is 47.64%, with operating and profit margins of 18.94% and 14.30%.
| Gross Margin | 47.64% |
| Operating Margin | 18.94% |
| Pretax Margin | 18.28% |
| Profit Margin | 14.30% |
| EBITDA Margin | 23.16% |
| EBIT Margin | 18.94% |
| FCF Margin | 1.12% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 0.92%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 0.92% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 22.06% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.92% |
| Earnings Yield | 3.66% |
| FCF Yield | 0.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Sep 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Imexpharm has an Altman Z-Score of 11.78 and a Piotroski F-Score of 5.
| Altman Z-Score | 11.78 |
| Piotroski F-Score | 5 |